Immunocore鈥檚听flotation in the听鲍厂听has听谤补颈蝉别d听$258 million.听听
The听pricing of its initial public offering听on the Nasdaq听in New York,听managed by听investment banks Goldman Sachs, JP Morgan and Jefferies,听is $158m higher than it expected in January.听
The Oxford-based company, which听delivers biological therapies that have the potential to transform the lives of people with serious diseases including cancer, has also raised $15m in a concurrent private placement. That takes the investment raised today to 拢200m.听
In January听Immunocore听revealed a 拢55m Series C funding round and closing of a听拢74m senior secured loan facility with Oxford Finance LLC.听
The news听followed positive Phase 3 trial interim analysis data for its lead programme听tebentafusp, which aims to help patients with metastatic uveal melanoma, a form of eye cancer.听听
The investments听are听intended to fund a potential commercial launch of听tebentafusp.听听
NHS doctors close 拢7m funding round for digital triage service eConsult听Health
CEO Bahija Jallal said last month: 鈥淭his successful financing represents another validating milestone for听Immunocore听as we continue our pioneering work in the field of soluble, bispecific TCR immunotherapies to treat a broad range of diseases.听听听
鈥淭he support of our new and existing investors represents a further endorsement of the potential of our powerful technology platform.听听听
鈥淔ollowing the recent positive Phase 3 data for听tebentafusp, we are working to progress this investigational agent through the regulatory process as a potential new treatment to metastatic uveal melanoma patients with a high unmet need.鈥澨�听
Immunocore听believes听tebentafusp听could be the first new therapy for the treatment of metastatic uveal melanoma in 40 years.听听
Commenting on the IPO, Darragh Lyons,听CEO of investor听Malin, said: “Immunocore’s听IPO is a significant milestone for the company…听It听expects to have several important clinical milestones during the second-half of 2021 and during 2022.”听